Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program - Absci (NASD

Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery

Absci starts human trial of ABS-201, monoclonal antibody designed with generative AI, in 24 months. For CTOs, it's the first proof of AI drug discovery compressing timelines; AMD partnership ($20M) signals generative AI penetration in regulated biotech.